<DOC>
	<DOCNO>NCT00764946</DOCNO>
	<brief_summary>A study test safety effect twice daily raltegravir diverse cohort patient currently infect human immunodeficiency virus ( HIV ) , least 50 % African American least 25 % female , either receive antiretroviral drug .</brief_summary>
	<brief_title>A Study Raltegravir Diverse Cohort HIV-Infected Patients ( 0518-055 )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patient HIV positive Patient agree use ( partner use ) birth control define study doctor If female , pregnant breastfeeding Patient use investigational agent last 30 day Patient acute hepatitis Patient receive MK0518 ( raltegravir ) Patient use another experimental HIVintegrase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>